3D MEDICINES(01244),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01244 3D MEDICINES

Not Yet Opened 01-21 15:58:27

5.170

-0.030

-0.58%

High5.560	Low5.110	Vol85.00K
Open5.200	D1 Closing5.200	Amplitude8.65%
Mkt Cap1.33B	Tradable Cap1.33B	Total Shares258.00M
T/O444.09K	T/O Rate0.03%	Tradable Shares258.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01244","market":"HK","secType":"STK","nameCN":"3D MEDICINES","latestPrice":5.17,"timestamp":1768982307083,"preClose":5.2,"halted":0,"volume":85000,"delay":0,"changeRate":-0.005769230769230817,"floatShares":258000000,"shares":258000000,"eps":-0.745688,"marketStatus":"Not Yet Opened","change":-0.03,"latestTime":"01-21 15:58:27","open":5.2,"high":5.56,"low":5.11,"amount":444090,"amplitude":0.086538,"askPrice":5.48,"askSize":2000,"bidPrice":5.17,"bidSize":10500,"shortable":0,"etf":0,"ttmEps":-0.716,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769045400000},"marketStatusCode":0,"adr":0,"listingDate":1671033600000,"exchange":"SEHK","adjPreClose":5.2,"openAndCloseTimeList":[[1768959000000,1768968000000],[1768971600000,1768982400000]],"volumeRatio":1.0429447851481048,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01244","defaultTab":"news","newsList":[{"id":"2602541198","title":"BRIEF-3D Medicines Inc Says Zhang Jing Resigns As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2602541198","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602541198?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:35","pubTimestamp":1768232125,"startTime":"0","endTime":"0","summary":"BRIEF-3D Medicines Inc Says Zhang Jing Resigns As CFOJan 12 (Reuters) - 3D Medicines Inc 1244.HK:ZHANG JING RESIGNS AS CFOLU XIAOHAO APPOINTED AS CFOFurther company coverage: 1244.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD16V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244","BK1161"],"gpt_icon":0},{"id":"1145832516","title":"3D MEDICINES (01244) Appoints Lu Xiao Hao as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1145832516","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145832516?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:06","pubTimestamp":1768226786,"startTime":"0","endTime":"0","summary":"3D MEDICINES (01244) announced that Ms. Zhang Jing has formally resigned from her position as the company's Chief Financial Officer; Mr. Lu Xiao Hao has been appointed as the new Chief Financial Officer, with the appointment taking effect immediately.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244","BK1161"],"gpt_icon":0},{"id":"2602543718","title":"3D Medicines Inc. Appoints Lu Xiaohao as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543718","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543718?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:02","pubTimestamp":1768226548,"startTime":"0","endTime":"0","summary":"3D Medicines Inc. has announced that Ms. Zhang Jing has resigned as Chief Financial Officer and Mr. Lu Xiaohao has been appointed to the role, effective immediately.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3D Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL8HLlFs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01244"],"gpt_icon":0},{"id":"2602543241","title":"3D Medicines Inc - Zhang Jing Resigns as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543241","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543241?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:02","pubTimestamp":1768226546,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD16V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01244","BK1161"],"gpt_icon":0},{"id":"2602372081","title":"BRIEF-3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2602372081","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602372081?lang=en_us&edition=fundamental","pubTime":"2026-01-09 23:15","pubTimestamp":1767971744,"startTime":"0","endTime":"0","summary":"BRIEF-3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab AcceptedJan 9  - 3D Medicines Inc 1244.HK:NEW DRUG APPLICATION FOR FIRST-LINE TREATMENT OF BILIARY TRACT CANCER OF ENVAFOLIMAB ACCEPTED BY NMPAFurther company coverage: 1244.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA04X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01244"],"gpt_icon":0},{"id":"1184618286","title":"3D MEDICINES (01244): New Drug Application for ENVAFOLIMAB as First-Line Treatment for Biliary Tract Cancer Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1184618286","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184618286?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:08","pubTimestamp":1767967697,"startTime":"0","endTime":"0","summary":"3D MEDICINES (01244) announced that the National Medical Products Administration (NMPA) has formally accepted the company's New Drug Application (NDA) for its commercial product ENVAFOLIMAB® (generic...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01244"],"gpt_icon":0},{"id":"2602937158","title":"3D Medicines Inc - New Drug Application for First-Line Treatment of Biliary Tract Cancer of Envafolimab Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2602937158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602937158?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:00","pubTimestamp":1767967254,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA04X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01244"],"gpt_icon":0},{"id":"2593434378","title":"BRIEF-3D Medicines Says Envafoimab Granted Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2593434378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593434378?lang=en_us&edition=fundamental","pubTime":"2025-12-23 01:27","pubTimestamp":1766424460,"startTime":"0","endTime":"0","summary":"BRIEF-3D Medicines Says Envafoimab Granted Orphan Drug DesignationDec 22 (Reuters) - 3D Medicines Inc 1244.HK:ENVAFOIMAB GRANTED ORPHAN DRUG DESIGNATIONDESIGNATION FOR TREATMENT OF GASTRIC CANCER AND ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS09K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01244"],"gpt_icon":0},{"id":"1167889245","title":"3D MEDICINES (01244): ENVAFOLIMAB® Granted Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1167889245","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167889245?lang=en_us&edition=fundamental","pubTime":"2025-12-22 22:16","pubTimestamp":1766412983,"startTime":"0","endTime":"0","summary":"3D MEDICINES (01244) announced that its commercialized product ENVAFOLIMAB® (generic name: Envafolimab Injection, R&D code: KN035) has officially received orphan drug designation for gastric cancer...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01244"],"gpt_icon":0},{"id":"2593433397","title":"3D Medicines Inc - Envafoimab Granted Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593433397?lang=en_us&edition=fundamental","pubTime":"2025-12-22 22:10","pubTimestamp":1766412602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS09K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01244","BK1161"],"gpt_icon":0},{"id":"2593433390","title":"3D Medicines Inc - Designation for Treatment of Gastric Cancer and - Gastro-Esophageal Junction Cancer Indications by China Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593433390?lang=en_us&edition=fundamental","pubTime":"2025-12-22 22:10","pubTimestamp":1766412602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS09K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01244","BK1161"],"gpt_icon":0},{"id":"1186879759","title":"3D Medicines Inc. (01244) Publishes November 2025 Monthly Return on Movements in Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1186879759","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186879759?lang=en_us&edition=fundamental","pubTime":"2025-12-04 12:04","pubTimestamp":1764821097,"startTime":"0","endTime":"0","summary":"3D Medicines Inc. discloses that the authorized share capital remained at 500 million ordinary shares, each with a par value of HKD 0.001, reflecting a total of HKD 500,000 as of November 30, 2025....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"gpt_icon":0},{"id":"2584758993","title":"Does 3D Medicines (HKG:1244) Have A Healthy Balance Sheet?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584758993","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584758993?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:55","pubTimestamp":1763506554,"startTime":"0","endTime":"0","summary":"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1244/3d-medicines-shares/news/does-3d-medicines-hkg1244-have-a-healthy-balance-sheet","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1244/3d-medicines-shares/news/does-3d-medicines-hkg1244-have-a-healthy-balance-sheet","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01244","EBIT","BK1161"],"gpt_icon":0},{"id":"1131812418","title":"3D Medicines Inc. (01244) Announces No Change in Share Capital for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1131812418","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131812418?lang=en_us&edition=fundamental","pubTime":"2025-11-05 12:03","pubTimestamp":1762315423,"startTime":"0","endTime":"0","summary":"3D Medicines Inc. (01244) reported that, as of 31 October 2025, its authorized share capital remained at 500,000,000 ordinary shares with a par value of HKD 0.001 each, totaling HKD 500,000. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"gpt_icon":0},{"id":"1104268280","title":"Hong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1104268280","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104268280?lang=en_us&edition=fundamental","pubTime":"2025-09-09 14:04","pubTimestamp":1757397871,"startTime":"0","endTime":"0","summary":"3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million. On the news front, 3D MEDICINES recently announced that the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244","BK1161"],"gpt_icon":0},{"id":"2564182188","title":"3D Medicines Narrows Loss in H1 as Revenue Edges Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2564182188","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564182188?lang=en_us&edition=fundamental","pubTime":"2025-09-01 17:15","pubTimestamp":1756718106,"startTime":"0","endTime":"0","summary":"3D Medicines  narrowed its attributable loss to 89.4 million yuan in the first half of 2025 from 103.5 million yuan a year prior, an Aug. 29 Hong Kong bourse filing said.Shares of the biopharmaceutical company were down nearly 3% in Monday afternoon trading.Loss per share was 0.36 yuan, down from 0.42 yuan in the year-ago period.Revenue for the interim period jumped 1.3% to 209.2 million yuan from 206.4 million yuan in the corresponding period of the last year, mainly due to a stable sales revenue.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01244","MDCO"],"gpt_icon":0},{"id":"2562380084","title":"3D Medicines Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2562380084","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562380084?lang=en_us&edition=fundamental","pubTime":"2025-08-28 17:14","pubTimestamp":1756372483,"startTime":"0","endTime":"0","summary":"3D Medicines Inc. has announced the successful administration of the first dose in humans for their novel radioactive drug conjugate 3D1015, referred to as 177Lu-PSMA-3D1015. This development is part of a clinical study aimed at evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer , a group with significant unmet clinical needs. The trial will focus on assessing the drug's safety profile, radiation dosimetry, and collecting extensive pharmacokinetic data and dose-exploration findings. These results will offer critical clinical evidence needed for determining dosage and managing risks in future registrational clinical trials. The company has not yet presented results from this study and advises shareholders and potential investors to exercise caution when dealing with the company's shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDLbmC37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01244"],"gpt_icon":0},{"id":"2560010247","title":"BRIEF-3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology","url":"https://stock-news.laohu8.com/highlight/detail?id=2560010247","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560010247?lang=en_us&edition=fundamental","pubTime":"2025-08-20 22:54","pubTimestamp":1755701675,"startTime":"0","endTime":"0","summary":"BRIEF-3D Medicines Inc Enters Strategic Agreement With Catug BiotechnologyAug 20 (Reuters) - 3D Medicines Inc 1244.HK:ENTERS STRATEGIC AGREEMENT WITH CATUG BIOTECHNOLOGYPARTIES TO LEVERAGE MRNA R+D PLATFORMFurther company coverage: 1244.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nFWN3UC0KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244","BK1161"],"gpt_icon":0},{"id":"1101274232","title":"3D MEDICINES (01244) to Partner with Kaituo Bio on tLNP Delivery and In Vivo CAR-T/NK Therapy Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1101274232","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101274232?lang=en_us&edition=fundamental","pubTime":"2025-08-20 22:52","pubTimestamp":1755701542,"startTime":"0","endTime":"0","summary":"3D MEDICINES (01244) announced that the company entered into a strategic cooperation framework agreement with Kaituo Bio on August 20, 2025. Under this agreement, both parties will collaborate in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4022","BK1161","CAR","01244"],"gpt_icon":0},{"id":"2560102933","title":"3D Medicines Inc - Parties to Leverage Mrna R+D Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2560102933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560102933?lang=en_us&edition=fundamental","pubTime":"2025-08-20 22:42","pubTimestamp":1755700979,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nFWN3UC0KL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01244","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3d-medicines.com","stockEarnings":[{"period":"1week","weight":-0.1282},{"period":"1month","weight":0.167},{"period":"3month","weight":-0.1511},{"period":"6month","weight":-0.1355},{"period":"1year","weight":0.7119},{"period":"ytd","weight":-0.03}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.0238},{"period":"6month","weight":0.0471},{"period":"1year","weight":0.3222},{"period":"ytd","weight":0.0372}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"3D Medicines Inc is a holding company mainly engaged in the research and development (R&D) and commercialization of biopharmaceuticals. The Company focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The Company has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The Company's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The Company also has a number of innovative drug research and development pipelines. The Company primarily operates in the domestic Chinese market.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.014907},{"month":2,"riseRate":1,"avgChangeRate":0.184703},{"month":3,"riseRate":0.333333,"avgChangeRate":0.065195},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.025133},{"month":5,"riseRate":0.666667,"avgChangeRate":0.093531},{"month":6,"riseRate":0.333333,"avgChangeRate":0.03295},{"month":7,"riseRate":0.333333,"avgChangeRate":0.019677},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.195829},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.13358},{"month":10,"riseRate":0,"avgChangeRate":-0.260453},{"month":11,"riseRate":0,"avgChangeRate":-0.194469},{"month":12,"riseRate":0.666667,"avgChangeRate":0.250685}],"exchange":"SEHK","name":"3D MEDICINES","nameEN":"3D MEDICINES"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"3D MEDICINES(01244),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 3D MEDICINES(01244) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"3D MEDICINES,01244,3D MEDICINES股票,3D MEDICINES股票老虎,3D MEDICINES股票老虎国际,3D MEDICINES行情,3D MEDICINES股票行情,3D MEDICINES股价,3D MEDICINES股市,3D MEDICINES股票价格,3D MEDICINES股票交易,3D MEDICINES股票购买,3D MEDICINES股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"3D MEDICINES(01244),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 3D MEDICINES(01244) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}